Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06922539 · ClinicalTrials.gov registry record · Phase 1

ST-001 nanoFenretinide in Relapsed/ Refractory Small Cell Lung Cancer

A Phase 1 study of Small-cell Lung Cancer, sponsored by SciTech Development.

Recruiting
Registry status
Phase 1
Development phase
44
Enrollment target
1
Study location

NCT06922539: Recruiting Phase 1 study of Small-cell Lung Cancer, sponsored by SciTech Development.

NCT06922539 is a Phase 1 study of Small-cell Lung Cancer that is actively recruiting participants, run by SciTech Development. The registered enrollment target is 44 participants, below the 232-participant average among 79 other Small-cell Lung Cancer trials with a reported enrollment target (81% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06922539, a Phase 1 study of Small-cell Lung Cancer, is actively recruiting participants, sponsored by SciTech Development.

RECRUITING
Registry status
Phase 1
Development phase
44 participants
Enrollment target
1
Study location

Study Summary

This study evaluates a fenretinide phospholipid suspension for the treatment of small cell lung cancer (SCLC).

Primary Outcome

Evaluate progression-free survival (PFS) in patients with relapsed or refractory small-cell lung cancer (SCLC) after prior platinum-based chemotherapy ± immunotherapy who are treated with ST-001 (12.5mg/mL) for IV Infusion, using a Simon 2-stage study design with an interim analysis for futility. PFS is defined as the time from start of treatment to disease progression (increase in tumor size, new metastases) or death.

Conditions Studied

Small-cell Lung Cancer

Interventions

  • DRUG Fenretinide

Study Locations (1)

California

  • University of Southern California - Los Angles

Trial Details

FieldValue
Enrollment Target 44 participants
Start Date 2025-12-11
Est. Completion 2028-10-01
Phase Phase 1
SciTech Development

2 total trials

What NCT06922539 shows while recruiting

NCT06922539 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 44 participants, a relatively small participant target, below the 232-participant average among 79 other Small-cell Lung Cancer trials with a reported enrollment target (81% lower).

The record links to 1 condition, with Small-cell Lung Cancer appearing as the primary indexed condition, and to 1 intervention - of which Fenretinide is the first listed.

NCT06922539 reports a single indexed study location in California.

Frequently Asked Questions

What is clinical trial NCT06922539 about?

NCT06922539 is a clinical study titled "ST-001 nanoFenretinide in Relapsed/ Refractory Small Cell Lung Cancer". This study evaluates a fenretinide phospholipid suspension for the treatment of small cell lung cancer (SCLC).

What is the current status of trial NCT06922539?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 44 participants. The study started on 2025-12-11. Estimated completion is 2028-10-01.

What conditions does trial NCT06922539 study?

This clinical trial studies the following conditions: Small-cell Lung Cancer.

What interventions are being tested in trial NCT06922539?

The interventions under investigation include: Fenretinide (DRUG).

Who is sponsoring clinical trial NCT06922539?

This trial is sponsored by SciTech Development, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06922539 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Small-cell Lung Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06922539's enrollment target sits among peer trials

44 54th of 79 higher than 26 of 79 other Small-cell Lung Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Small-cell Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02323945 · 44 participants · NA

    Effects of Breathing Mild Bouts of Low Oxygen on Limb Mobility After Spinal Injury

  • NCT03093909 · 44 participants · Phase 1

    Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases

  • NCT03104491 · 44 participants · Phase 1

    Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia

  • NCT03781765 · 44 participants · Phase 4

    Stimulant vs. Non-stimulant Treatments and Reward Processing in Drug-naive Youth at SUD Risk

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT06922539

Source: ClinicalTrials.gov NCT06922539, the US trial registry maintained by the National Library of Medicine. NCT06922539 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.